





REMAP-CAP SITE INITIATION VISIT UK - PAEDIATRICS

VERSION 5.1 16 DEC 2024

AGENDA

REMAP-CAP

- Meet the team
- Trial design
- Protocol
- Safety
- Study procedures
- ICH-GCP & GDPR
- Practical information





REMAP-CAP MEET THE TEAM

SPONSORS AROUND THE GLOBE



TEAM INTRODUCTION: SPONSOR

Lead Investigator EU: Lennie Derde

Co-lead Investigator EU: Marc Bonten

Co-Investigator EU: Helen Leavis, Marjolein Hensgens

Medical Monitor EU: Lennie Derde, Marjolein Hensgens, Anthony Gordon

Country PM: Lina Malkova

Country CTA: Sonal Patil



REMAP-CAP Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia



TEAM INTRODUCTION: COUNTRY

Country lead PI: Prof Anthony Gordon

UK Management: Imperial College London

UK CTU: ICNARC

UK Management & Monitoring Team: Janis Best-Lane, Aisha Anjum, Lucy Stronach, Beren Barklam, Lindsay Jack, Elizabeth Fagbodun, Tina Reetun, and Walton Charles





REMAP-CAPTRIAL DESIGN


TRIAL DESIGN: ADAPTIVE PLATFORM TRIAL (APT)

- Traditional RCTs
- Serial testing of single hypotheses
- Set randomization ratio




APT – REMAP-CAP

- Parallel testing of multiple hypotheses
- Adaptive
 - Interventions added or removed over time Response Adaptive Randomization (RAR)




TRIAL DESIGN: MODULAR PROTOCOL STRUCTURE





REMAP-CAP PROTOCOL CORE PROTOCOL AND PANDEMIC APPENDIX TO CORE



PATIE	NT POPULATION				
	Non-pandemic subjects (CAP)	Non-pandemic subjects (FLU)		Pandemic subjects (COVID-19)	
Strata	PINSNP (Pandemic infection is neither suspected nor proven)	PINSNP (Pandemic infection is neither suspected nor proven)		PISOP (Pandemic infection is suspected or proven)	
Patients	Adults			Adults	
	Admitted to Hospital for CAP			Admitted to hospital for acute illness (suspected to be) caused by pandemic infection	
States	<u>Severe</u> receiving organ failure support in an ICU	<u>Moderate</u> Ward patient, OR admitted to an ICU but not receiving organ failure support	<u>Severe</u> receiving organ failure support in an ICU	<u>Moderate</u> Ward patient, OR admitted to an ICU but not receiving organ failure support	<u>Severe</u> receiving organ failure support in an ICU

ELIGIBILITY CRITERIA – CORE PROTOCOLV3.I

Inclusion Criteria

1. Adult or paediatric patient (28 days or older) hospitalised with an acute illness due to a lower respiratory tract infection

ELIGIBILITY CRITERIA – CORE PROTOCOLV3.I

Exclusion Criteria

- 1. More than 14 days has elapsed since admission to hospital
- 2. If receiving organ failure support in an ICU, more than 48 hours has elapsed since admission to ICU
- 3. Expected to be discharged from this hospital admission within the next 24 hours
- 4. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.
- 5. Previous participation in this REMAP within the last 90 days

ENDPOINTS		ndpoints will be merged n the next Protocol
	Non-pandemic subjects	Pandemic subjects
Primary	Day 90 mortality	Day 21 mortality and organ support free days
Secondary	Day 180 mortality / Quality of Life Questionnaire	Day 90 mortality and Day 180 mortality / Quality of Life Questionnaires

Remember

Endpoints require timely entry in the eCRF

Response Adaptive Randomization!

REMAP-CAP DOMAIN SPECIFIC APPENDICES (DSA)

Refer to DSAs for:

- Domain rationale
- Domain specific eligibility criteria & interventions
- Concomitant care
- Potential domain-specific adverse events
- Domain-specific endpoints
- Domain-specific protocol deviations
- **Other** domain specific information

Domain summary slides are part of this SIV training In addition **review DSA and DSA training slides**



****All treatments should commence immediately after randomisation****

Reach out to the Project Team with any **questions**



NON-PANDEMIC FLU STRATA - INFLUENZA ANTIVIRAL DOMAIN -CORTICOSTEROID DOMAIN

BACKGROUND - INFLUENZA

Seasonal influenza estimated ~ 300,000 to 650,000 deaths worldwide annually

Currently, recommended antiviral agents for influenza (**oseltamivir**) have **not been studied** in placebo controlled randomised trials to demonstrate survival benefit in hospitalized patients with influenza

Widely used in clinical practice

Baloxavir is a newly approved antiviral with evidence of benefit in outpatients on time-to-symptom resolution, but no evidence of benefit in inpatients

Whether it has value by itself, or in combination with oseltamivir, in inpatients is an open question

INFLUENZA ANTIVIRAL DOMAIN

VERSION 2.1, 14FEB23

Domain	Strata	State	Patients	Intervention	Administered
Influenza	Non-pandemic	Severe & Adults & Children		I1 - No antiviral for influenza	-
Antiviral (A)	and pandemic m FLU (ie co- infections are eligible)			I2 - 5 days of Oseltamivir	5 days / discharge
				I3 - 10 days of Oseltamivir	10 days / discharge
				I4 - Baloxavir	Days 1 and 4 / discharge
				I5 - 5 days Oseltamivir and Baloxavir days 1 and 4	5 days OT and day 1 and 4 Balox / discharge
				I6 - 10 days Oseltamivir and Baloxavir days 1 and 4	10 days OT and day 1 and 4 Balox / discharge

ELIGIBILITY CRITERIA – INFLUENZA ANTIVIRAL DOMAIN

Inclusion Criteria

- 1. Adult or paediatric patient (28 days or older, CGA)
- 2. Influenza infection is confirmed by microbiological testing

ELIGIBILITY CRITERIA – INFLUENZA ANTIVIRAL DOMAIN

Exclusion Criteria

- 1. Moderate state: More than 96 hours since hospital admission
- 2. Severe state: More than 48 hours since ICU admission
- 3. Already received 2 doses of oseltamivir (or any other neuraminidase inhibitor) or 1 dose of baloxavir other neuraminidase may include zanamivir and peramivir
- 4. Known hypersensitivity to agents
- 5. Pregnancy (baloxavir interventions only)
- 6. Clinician does not feel best interests in participating

INFLUENZA ANTIVIRAL INTERVENTIONS (ADULTS & CHILDREN)

No antiviral agents active against influenza - Do not prescribe any antiviral active against influenza, including oseltamivir until the end of study day 28 or hospital discharge, whichever occurs first

Oseltamivir

•	5-days of oseltamivir*	Prescribe a 5-day course of oseltamivir commencing immediately after randomization – (10 doses with BD administration)
•	10-days of oseltamivir	Prescribe a 10-day course of oseltamivir commencing immediately after randomization – (20 doses with BD administration)

Can use hospital stock of Oseltamivir. Dosing for adults & children in as per local guidelines.

Standard adult dose is of Oseltamivir is 75 mg enterally BD - Dosing for children is 6 mg/kg/day, divided into two doses up to children of 40kg.

See protocol for dose adjustment for renal dysfunction

Cease all treatment after the treatment course (5 days / 10 days) or after hospital discharge, whichever occurs first.

*5-days of oseltamivir - For continuity across regions, important for all sites to participate in this intervention

INFLUENZA ANTIVIRAL INTERVENTIONS

Baloxavir (adults & children)

 Baloxavir on days 1 and 4 	Given on days 1 and 4 , can give an added dose on day 7 if the treating clinician feels it is clinically indicated	
Combination		
Baloxavir + 5 days oseltamivir	Baloxavir given on days 1 and 4 and oseltamivir given for 5 days (10 doses oseltamivir with BD administration)	
Combination		
Baloxavir + 10 days oseltamivir	Baloxavir given on days 1 and 4 and oseltamivir given for 10 days (20 doses oseltamivir with BD administration)	

Baloxavir is supplied by Roche (via study team), can use hospital stock too if available. Baloxavir dose: <40kg = 2mg/kg (max dose of 40mg), 40-80kg = 40mg, >80kg = 80mg No adjustment for renal/hepatic impairment

SWAB COLLECTION (ANTIVIRAL DOMAIN ONLY)

- After site activation nasal swab kits/safe boxes will be provided to site.
- Please collect nasal swabs from ALL positive influenza patients on the following days:-
 - Day 1 (soon after randomisation)
 - Day 3 (+/- 24 hrs or asap if D3 not possible)
 - Day 7 (+/- 24 hrs or asap if D7 not possible)
- Please post patients' Day 1 and Day 3 samples together in one safe box. Do not wait for Day 7 sample to be taken as samples are not viable after 5 days. Day 7 sample to be sent separately.
- Please enter sample collection on the eCRF

SWAB COLLECTION (ANTIVIRAL DOMAIN ONLY)

Notes:

- Subsequent sample(s) should be taken even if a sample is missed.
- Please do not use hospital swabs as these are not the correct type that we require for the study
- Sites may use a sample tracker if they wish Influenza Antiviral Swab Tracker VI.0 30.01.2024 Remapcap-UK

Xmas/Easter

Do not send swab samples as central labs are closed – keep refrigerated until labs are open.

If you have no refrigeration space, miss the samples, it will not be PD

BACKGROUND - CORTICOSTEROIDS

- Several RCTs and meta-analyses have suggested benefit of treatment with corticosteroids, however existing evidence is not definitive, and corticosteroids have a range of potentially adverse effects
- Potential benefit appears to be more likely for patients who are severely ill
- Uncertainty about the use of corticosteroids in:
 - Patients with CAP due to influenza
 - Patients with septic shock vs those without septic shock
 - Patients with ARDS vs no ARDS.

CORTICOSTEROID DOMAIN

VERSION 5.0, 09NOV22

Adults

Domain	Strata	State	Intervention	Administered
Corticosteroid (C) Non-pandemic Severe		Severe	C1 - No corticosteroid	-
	CAP & FLU		C3 - Shock-dependent hydrocortisone	During septic shock
			C4 – Fixed-course dexamethasone	10 days
	Non-pandemic CAP & FLU	Moderate	C1 - No corticosteroid	
			C4 – Fixed-course dexamethasone	10 days

Children

Domain	Strata	State	Intervention	Administered
Corticosteroid (C)	Non-pandemic	Severe C1 - No corticosteroid		-
	CAP & FLU		C4 – Fixed-course dexamethasone	10 days
	Non-pandemic CAP & FLU	Moderate	C1 - No corticosteroid	-
			C4 – Fixed-course dexamethasone	10 days

ELIGIBILITY CRITERIA – CORTICOSTEROID DOMAIN

Inclusion Criteria

- 1. Adult or paediatric patient (28 days or older, CGA)
- 2. If in the Moderate State, receiving some form of supplemental oxygen
 - Simple facemask, low- or high-flow oxygen, or non-invasive ventilation

ELIGIBILITY CRITERIA – CORTICOSTEROID DOMAIN

Exclusion Criteria

- 1. Intention to prescribe systemic corticosteroids for a reason that is unrelated to the current episode of CAP/FLU (or direct complications of CAP)
- 2. More than 24h have elapsed since ICU admission (if in the Severe State)
- 3. Known hypersensitivity to any corticosteroid
- 4. The treating clinician believes that participation in this domain is not in the best interests of the patient

Note: If in the Moderate State, platform exclusion applies - More than 14 days have elapsed while admitted to hospital

CORTICOSTEROID INTERVENTIONS

No Corticosteroids -

Adults & Children

Do not prescribe any systemic corticosteroid, including hydrocortisone or dexamethasone until the end of study day 28 or hospital discharge, whichever occurs first. Administration of systemic corticosteroids for the treatment of new illnesses that develop in the course of a patient's ICU stay (i.e., not resulting from CAP/FLU or its direct complications) is permitted

 Shock-dependent hydrocortisone -Adults Only
 Commence hydrocortisone IV 50 mg 6 hourly when patient is in septic shock*, cease once clinician believes septic shock is resolved, note that septic shock is always considered to be resolved when vasopressors have not been administered via infusion in the preceding 24 h

Fixed dose dexamethasone -Adults & Children

Prescribe dexamethasone (IV or enteral), adults 6mg / children 0.15 mg/kg (max 6mg) daily, cease after 10 days or hospital discharge, whichever occurs first. See protocol for pregnancy requirements. If patient develops septic shock, a switch from dexamethasone to hydrocortisone is permitted.

Can use hospital stock of hydrocortisone and dexamethasone

*See protocol for septic shock definition



REMAP-CAP SAFETY

SAFETY - DEFINITIONS

Event	Definition	Causal relation Necessary
Adverse Event (AE)	Any untoward medical occurrence in a subject to whom a medicinal product is administered	NO
Serious Adverse Event (SAE)	 Any untoward medical occurrence that at any dose requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, results in a congenital anomaly or birth defect, is life-threatening, or results in death 	NO
Domain specific SAE's	Safety events defined in the Domain Specific Appendices	YES
Suspected Unexpected Serious Adverse Reactions (SUSAR)	'Unexpected serious adverse reaction' means a serious adverse reaction, the nature, severity or outcome of which is not consistent with the reference safety information	YES

SAFETY - REPORTING

Event type	Reporting required per protocol
SAE's <u>related</u> to a study intervention or study participation (including SUSARs)	YES (from randomization to hospital discharge)
SAEs <u>not related</u> to study intervention or study participation	NO (unless needed per country requirements)
AE's	NO (unless needed per country requirements)
Domain-specific SAE's	YES (refer to DSA for details)
Domain-specific secondary endpoints	YES - report as SAE <u>and</u> endpoint for SAE's related to study intervention or study participation
	NO - for SAE's not related to a study intervention or study participation, unless needed per country requirements – report endpoints via eCRF discharge page

SAFETY - REPORTING

Report safety event within 24 hours of becoming aware of	SAE types	
Investigator accesso relatedrage	Not related	
Investigator assesses relatedness,		Unlikely to be related
expectedness, Expected		Possibly related
severity,	to be	Probably related
Severity,	reported	Definitely related
seriousness	J	

Use an SAE form in the eCRF	Back-up SAE form available in ISF	Document relevant information in the patient file
	E-mail to:	
	eu.remapcap@umcutrecht.nl	Follow up with patient until SAE is
	ukremap-cap@icnarc.org	resolved

SAFETY - REPORTING

SAE report types:

- Initial SAE report
- Follow-up SAE report
- Final SAE report Print and file in ISF

Medical Monitor reviews all reported safety events

The monitor will follow up on any requests from the Medical Monitor.

The Data Safety Monitoring Board monitors overall safety for REMAP-CAP.





REMAP-CAP INFORMED CONSENT

INFORMED CONSENT - DEFINITION

'a process by which a <u>subject voluntarily confirms</u> his or her <u>willingness to participate</u> in a particular trial, after having been <u>informed of all aspects of</u> <u>the trial</u> that are relevant to the subject's decision to participate. Informed consent is <u>documented by</u> means of a <u>written</u>, signed and dated <u>informed</u> <u>consent form</u>' (ICH-GCP)

INFORMED CONSENT PROCESS - WHO

Consent types	Definition	Involved	Use	
Parent / guardian	Consent obtained from parent/ guardian	Subject Parent/guardian	When parent/guardian has capacity	
ProLR consent	Consent obtained from a person other than the parent/ guardian	ProLR: Clinician independent of the study for child	When parent/guardian does not have capacity or is not available to consent and ProLR is present.	ALWAYS IN ACCORDANCE WITH APPROVED PROCESSES PER
Witnessed consent	Consent obtained in the presence of an impartial witness	Subject Parent / guardian Impartial witness: Visitor or independent nurse	Required when parent/guardian/ cannot write and verbal consent is taken instead of written consent <u>or</u> When remote consent is obtained (via telephone)	LOCAL LAW AND REGULATION


INFORMED CONSENT PROCESS - WHEN

Consent types	Time point	Involved	Use	
Prospective consent	Consent obtained prior to start of screening activities	Parent/guardian (witness, if verbal/remote)	When parent/guardian has capacity.	
Deferred consent	Consent obtained prior to screening activities	ProLR	When parent/guardian doesn't have capacity or not available and ProLR is present.	ALWAYS IN ACCORDANCE
Delayed consent	Consent obtained after patient is enrolled in study	Parent/guardian or ProLR (witness, if verbal/remote)	In emergency setting when parent/ guardian doesn't have capacity or is not available and ProLR also not available. Consent must be attempted/obtained as soon as possible from parent/guardian or ProLR (ideally within 24 hrs).	WITH APPROVED PROCESSES PER LOCAL LAW AND REGULATION
Retrospective consent	Consent obtained after patient is enrolled in study	Parent/guardian (witness, if verbal/remote)	Where only ProLR consent was obtained. Obtained when parent/guardian is available and capacity is regained.	

INFORMED CONSENT PROCESS - HOW

Consent types	Applied when	Involved	Documentation	
Written consent	Parent/guardian or ProLR, can write	Parent/guardian ProLR	Documented on a paper Informed Consent Form (ICF) – written version.	
Verbal consent	Parent/guardian <u>cannot read or write</u>	Parent/guardian Impartial witness	Documented on a paper Informed Consent Form (ICF) – written version with witness section completed.	<u>ALWAYS</u> IN ACCORDANCE WITH APPROVED
Remote / Telephone consent	Parent/guardian and site staff are not in the same location or cannot be present in person promptly <u>or</u> When patient is d/c from hospital promptly and retrospective parent/ guardian consent is required	Parent/guardian Impartial witness	Documented on a paper Informed Consent Form (ICF) – telephone version with witness section completed. Also obtain written consent from parent/guardian if possible.	PROCESSES PER LOCAL LAW AND REGULATION
Video consent	Parent/guardian have requested information in a different format	Parent/guardian	Documented on a paper Informed Consent Form (ICF) – video version. Provide copy of full PIS too.	

INFORMED CONSENT PROCESS - ADULTS - FLOWCHART



INFORMED CONSENT PROCESS – PAEDIATRICS

The following consent forms are available:-

- Young Child and Guardian To be used where children are <10 years old
- Children and Guardian 10-15 For children 10-15yrs old
- Child 16-17 For children between 16-17 yrs old

Waiting to be approved as part of Am42:

- Telephone consent form
- Video consent form
- Summary IS/CF

INFORMED CONSENT PROCESS - DOCUMENTATION

Documentation must include information regarding:

- Who informed the parent/guardian/ProLR about the study and when was this interview held.
- Method for obtaining informed consent (including alternative methods during a pandemic).
- For parent/guardian consent: Confirmation status was adequate to decide on study participation.
- For ProLR consent: Verification of status i.e. independent of study

Additional preferred items:

- Parent/guardian/ProLR were **able to ask questions** from a study investigator
- Parent/guardian/ProLR was **given enough time** to consider study participation
- Which version of the ICF was signed
- Parent/guardian/ProLR were given a copy of the PIS/ICF

It should be clear from the documentation site adhered to site and REMAP-CAP approved procedures for obtaining Informed Consent.



REMAP-CAP STUDY PROCEDURES

SCREENING

Site specific eligibility checklist to be printed/downloaded from eCRF (Spinnaker)

Complete screening and enrolment log

Eligible patients entered in eCRF and go through the **digital** eligibility assessment

Subject randomized, or if screen failure \rightarrow moved to Registry list

What is your screening method?

SUBJECT RECRUITMENT

Important to have a clear recruitment strategy

Who is involved in subject recruitment?

Who is responsible for subject recruitment?

What is your target recruitment frequency?

Any expected challenges?

How is REMAP-CAP shared with non-study staff?

Can we provide support?

What is your recruitment strategy?

RANDOMISED SUBJECTS

- Treat patients according to protocol & randomization result
- Study participation must be visible in patient (electronic) file
- If applicable: order study drugs
- Complete eCRF pages (can be weekly)
 - Enter endpoint data on time (notification is sent)

If subject withdrawn from treatment	If subject withdraws consent
Document reason in source	Consent event eCRF needs to be completed The patient will be locked in the eCRF

PROTOCOL DEVIATIONS - DEFINITIONS

	PD category	Minor	Major
1	Violation of one or more of the eligibility criteria	Violation of 1 of the eligibility criteria, not affecting subject safety.	Violation of > 1 of the eligibility criteria, or 1 deviation that affects subject safety.
2	Incorrect study treatment/drug dosing	≥2 doses of Oseltamivir missed≥1 doses of Baloxavir missed	> 2 dose errors
3	Use of protocol prohibited concomitant care	-	Always major
4	SAE	Late reporting / incorrect or incomplete reporting	Unreported SAE
5	ICF	Incorrect version or completion ICF / ICF process	Missing ICF
6	Missing study data or (primary) endpoint	Missing data (no endpoint)	Missing endpoint data
7	Other deviation/violation	At the discretion of the monitor; deviation major.	when in doubt consider the
8	Domain specific protocol deviations	Refer to the Domain specific appersection of the specific protocol deviations.	endices for definitions of domain

PROTOCOL DEVIATIONS - REPORTING

Protocol deviations (PD) must be:

- Reported to the monitor
- Entered in the eCRF (per eCRF completion guideline)
- Signed off by the PI

In the eCRF

- Platform eligibility deviations
- Domain-specific deviations

For any other deviation use:

• Platform eligibility deviations => 'OTHER'

PDs are listed in the follow-up letter File in ISF

Domain-specific deviations:

- Randomized but ineligible
- Allocated IMP not administered per protocol
- Received prohibited empiric IMP

INVESTIGATIONAL MEDICINAL PRODUCT (IMP)

Supply via:


- Hospital stock
- Pharmaceutical company

Ordering/procurement:

- Hospital stock: Via regular procedure of hospital pharmacy.
- External supply (pharmaceutical company): Via drug order request form.

Storage conditions per:

- SmPC (section 6.3 and 6.4) (only for registered medication)
- Pharmacy Guide





Preparation & administration per:

- Domain Specific Appendix
- Administration guide
- Pharmacy guide

Drug accountability at Pharmacy level:

- For marketed IMPs, Pharmacy inventory logs should be made available to the sponsor upon request for
 - IMP that is part of hospital stock, managed by hospital Pharmacy (routine records)
 - IMP provided by Sponsor/external, managed by Clinical Trials Pharmacy
- For unmarketed IMPs: This will always be managed by Clinical Trials Pharmacy and study specific inventory log templates will be provided

Drug accountability at ICU/Ward level

Marketed IMP: Dispensing accountability only, returns not required/accounted for

REMAP-CAP Study drug Accountability Log

EudraCT number	2015-002340-14	Site Name	
PI Name		Site Number	

<u>Complete</u>	<u>this part wh</u>	en collecting IN	<u> AP from Pharma</u>	icy:	Complete	e this part who	en using the stu	dy drug on IC	<u>U:</u>
Date (dd/mm/ygd)	Batch No.	Study Drug name	Study drug serial number	Expiry date (dd/mm/yy)	Collected from Pharmacy by (Initials)	Date <u>used</u> (dd/mm/yy)	Administered as per Protocol (Y/N)	Patient study ID	Monitor Review (initial & date)
						-			

Original to be kept in Investigator Site File.

Unmarketed IMP: Dispensing + returns logged, individual patient accountability logs

Subject Drug Accountability Form

					Use 1 form per dr	ug per subject			
Site	code (ABC-XYZ): A	BC		PI name: Lennie Derde			Subject num	ıber (Spiral): 01999	00001
	; (compound): DM		iministration		rade name): Repage	ermanium		& strength: 120 mg s per bottle)	per capsule
Line #	Date dispensed	Amount & Units ¹ dispensed; Route	Lot / Ba Number		Expiry date	Dispensed by (initials + date ²)	Amount & Units ¹ remaining / returned ³	Accountability completed by (initials + date ²) ³	CRA review (initials + date) ³
1	1 Apr 2020	120 mg = 1 capsule	X1234	5	02 Sept 2024	HP 1 Apr 2020	29 capsules	HP 1 Apr 2020	
2	2 Apr 2020	120 mg = 1 capsule	X1234	5	02 Sept 2024	HG 2 Apr 2020	28 capsules	HG 2 Apr 2020	
3	2 Apr 2020	120 mg = 1 capsule	X1234	5	02 Sept 2024	RW 2 Apr 2020	27 capsules	RW 2 Apr 2020	
4	3 Apr 2020	120 mg = 1 capsule	X1234	5	02 Sept 2024	HP 3 Apr 2020	26 capsules	HP 3 Apr 2020	
5	3 Apr 2020	120 mg = 1 capsule	X1234	5	03 Sept 2024	SS 3 Apr 2020	25 capsules	AD 3 Apr 2020	

¹ Example: 20 tablets, 3 ml, etc.

Page 1 of 1

³ Only applicable for IMPs without marketing authorization

² Enter date of completion and signed initials. Staff member must be listed on the Authorization Form.

Temperature control:

- For marketed IMPs: Temperature monitoring/excursions to be managed as per local processes. Any concerns submitted/discussed with Sponsor. Records to be made available to Sponsor upon request.
- For unmarketed IMPs: Temperature monitoring and study specific excursion forms to be maintained. Study templates will be provided.

Return and destruction:

- Hospital stock: Via routine local procedures
- Sponsor/external stock: Sponsor must be contacted. Study templates will be provided, but local destruction forms can be used.

Local pharmacies are responsible for monitoring expiration dates of IMPs throughout the study.

INVESTIGATOR SITE FILE

A (digital) Investigator Site File (ISF) is provided

ISF tasks:

- File received ISF document updates and correspondence
- Add documents of team members
- Add updates of certificates
- Keep logs up-to-date
- Use document referral notes to document where to

find specific documents (if not filed in standard location of ISF)

Site responsibility to keep the ISF upto-date



INVESTIGATOR SITE FILE: INDEX

- 1. Contact Information Study
- 2. Regulatory and Ethical documents
- 3. Financial Contracts / Signed Agreements
- 4. Study Protocol
- 5. Research Subject Information
- 6. WMO Subject Insurance
- 7. Site Personnel
- 8. Monitoring / Audit / Inspection documents
- 9. Working Procedures
- 10. Product Information / Pharmacy
- 11. Laboratory

12. Safety (including SAE forms)
13. Case Report Form (CRF)
14. File Notes
15. Documents of attended meetings
16. Lab Labels, request forms, shipment forms
17. Correspondence
18. Other





REMAP-CAP ICH-GCP & GDPR

ICH-GCP: INVESTIGATOR RESPONSIBILITIES

The investigator is **responsible for supervising** any individual or party to whom the investigator delegates **trial-related duties and functions** conducted at the trial site.

The investigator has **overall responsibility** for all aspects of the trial conducted at site. The investigator must ensure the trial is conducted in accordance with:

ICH-GCP and applicable regulatory requirements.

ICH-GCP: SOURCE DATA

The investigator/institution should maintain adequate source documents and trial records.


Source data should be: attributable, legible, contemporaneous, original, accurate, and complete.

Changes to source data should be:

- Traceable (with date and signed initials),
- Not obscure the original entry,
- and be explained if necessary

Direct entry of data is permissible for some data

The source must be clear from the source data location log



GDPR

Applicable in the European Union	Requirements for processing (collecting, using and retaining) personal data and the rights of data subjects	Subjects give explicit permission to use data on the informed consent form	Refer to <u>https://gdpr-</u> info.eu/
 At site: Documents and dat Study data collected No patient identifie Only subject number 	d in eCRF rs in eCRF	 Study data processing: eCRF server in Australia Data transfer and process 	sing according to GDPR



REMAP-CAP PRACTICAL INFORMATION

SITE ACTIVATION

Required documents

- Study / site / PI approval by CA, CEC and LEC
- Fully signed Clinical Trial Agreement
- Site specific ICF form
- Subject insurance
- Normal values or ranges
- CV / GCP certificate
- Site confirmation of IMP receipt (if centrally supplied)
- (Digital) ISF at site

Forms to be completed by site:

- Protocol Acceptance Form
- Domain choice pages
- Delegation Log
- Spiral database form
- Source Document Location Log
- Retention of records statement
- Self-training log: training of Domains
- SIV training attendance Log
- Monitor visit log for SIV

Site activation!

Green Light Letter and Site-specific ICF is sent

eCRF account is activated

Enrolment can start!

Complete



INTERIM MONITORING AND FURTHER SITE CONTACT


First monitor visit	Next monitor visit	Monitor contact
after 3 subjects enrolled or within 6 months of first patient inclusion	every 6 months, every year or every 2 years (depending on site performance)	Regular contact moments with monitor to discuss study & recruitment status

- **Invoice payment** start-up fee and patient-fees (as per contract)
- Audits/Inspections please notify the Sponsor immediately when announced

ELECTRONIC SOURCE DATA AND MONITORING

Requirements for electronic patient records:

- Access rights regulated
- Security systems in place
- Laboratory values etc. can be evaluated electronically (checked for clinical significance)
- Audit trail
- Read only monitor account



Certified copies can be used if read only access (or audit trail) is not possible

Or **'over the shoulder access'** with site staff member

PLATFORM CONCLUSIONS & PUBLICATIONS

Platform conclusions can lead to Domain (intervention) changes

• Sites will be notified about platform conclusion

Platform Conclusion relevant to public health:

- Presentation and/or publication
- Site staff is listed as collaborators

Sites may not publish or present interim or definite results

CLOSE-OUT

In theory, REMAP-CAP will run indefinitely

Limiting factors

- Funding
- Poor site performance
- Site request to stop recruitment
- All scientific questions have been answered

Close-Out visit by CRA/Sponsor

Study records must be retained for **25 Years**

STAY UP TO DATE

REMAP-CAP communication channels

- <u>www.remapcap.org</u> / <u>www.remapcap.eu</u>
- Recruitment updates
- <u>Newsletters</u>
- Podcast, We4U (recordings), Instagram, LinkedIn, Twitter

14,133

Patient

7,498

Total patients



	Patient andomisations	Patient randomisations with suspected or	28 Available interventions in 10	REMAP-CAP
7			domains	A Randomised, Embedded, Multi-factorial, Adaptive
	fotal patients	Patients with suspected or proven COVID-19	199 Active sites in Europe	Platform trial for Community-Acquired Pneumonia Learn more

🖻 🖈 🗖 🌑



← → C â remapcap.eu

CLOSING MESSAGE

UK Trial Management Contacts: <u>ukremap-cap@icnarc.org</u> Aisha Anjum 07956 800722 Janis Best-Lane 07714 051680 Lucy Stronach 07714 051401



For urgent situations outside UK office hours +31 (0) 6 277 444 77 Eu.remapcap@umcutrecht.nl







#REMAPCAPFAMILY